Stcube & Co., Inc.

University of Texas System

Michael Joseph Surace

Stephen Sunghan Yoo

Steven Hsesheng Lin

Amrish Sharma

Yong-Sik Bong

Kyu Lee Han

Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Also included are molecules having an antigen binding fragment that immunospecifically bind to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Also provided are methods for treating anti-PD-1 therapy or anti-PD-L1 therapy resistant or refractory cancers.

Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1

Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.

Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof

Growing community of inventors

Germantown, MD, United States of America

Michael Joseph Surace